Now showing items 1-17 of 17

    • Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. 

      Moynihan, C; Bancroft, EK; Mitra, A; Ardern-Jones, A; Castro, E; Page, EC; Eeles, RA (2017-11)
      OBJECTIVE: Increased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male ...
    • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. 

      Hamdi, Y; Soucy, P; Kuchenbaeker, KB; Pastinen, T; Droit, A; Lemaçon, A; Adlard, J; Aittomäki, K; Andrulis, IL; Arason, A; Arnold, N; Arun, BK; Azzollini, J; Bane, A; Barjhoux, L; Barrowdale, D; Benitez, J; Berthet, P; Blok, MJ; Bobolis, K; Bonadona, V; Bonanni, B; Bradbury, AR; Brewer, C; Buecher, B; Buys, SS; Caligo, MA; Chiquette, J; Chung, WK; Claes, KBM; Daly, MB; Damiola, F; Davidson, R; De la Hoya, M; De Leeneer, K; Diez, O; Ding, YC; Dolcetti, R; Domchek, SM; Dorfling, CM; Eccles, D; Eeles, R; Einbeigi, Z; Ejlertsen, B; EMBRACE; Engel, C; Gareth Evans, D; Feliubadalo, L; Foretova, L; Fostira, F; Foulkes, WD; Fountzilas, G; Friedman, E; Frost, D; Ganschow, P; Ganz, PA; Garber, J; Gayther, SA; GEMO Study Collaborators; Gerdes, A-M; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gronwald, J; Hahnen, E; Hamann, U; Hansen, TVO; Hart, S; Hays, JL; HEBON; Hogervorst, FBL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Jakubowska, A; James, P; Janavicius, R; Jensen, UB; John, EM; Joseph, V; Just, W; Kaczmarek, K; Karlan, BY; KConFab Investigators; Kets, CM; Kirk, J; Kriege, M; Laitman, Y; Laurent, M; Lazaro, C; Leslie, G; Lester, J; Lesueur, F; Liljegren, A; Loman, N; Loud, JT; Manoukian, S; Mariani, M; Mazoyer, S; McGuffog, L; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mulligan, AM; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nussbaum, RL; Olah, E; Olopade, OI; Ong, K-R; Oosterwijk, JC; Osorio, A; Papi, L; Park, SK; Pedersen, IS; Peissel, B; Segura, PP; Peterlongo, P; Phelan, CM; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Richardson, A; Robson, M; Rodriguez, GC; Rookus, MA; Schmutzler, RK; Sevenet, N; Shah, PD; Singer, CF; Slavin, TP; Snape, K; Sokolowska, J; Sønderstrup, IMH; Southey, M; Spurdle, AB; Stadler, Z; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Tan, Y; Tea, M-K; Teixeira, MR; Teulé, A; Teo, S-H; Terry, MB; Thomassen, M; Tihomirova, L; Tischkowitz, M; Tognazzo, S; Toland, AE; Tung, N; van den Ouweland, AMW; van der Luijt, RB; van Engelen, K; van Rensburg, EJ; Varon-Mateeva, R; Wappenschmidt, B; Wijnen, JT; Rebbeck, T; Chenevix-Trench, G; Offit, K; Couch, FJ; Nord, S; Easton, DF; Antoniou, AC; Simard, J (2017-01)
      PURPOSE: Cis-acting regulatory SNPs resulting in differential allelic expression (DAE) may, in part, explain the underlying phenotypic variation associated with many complex diseases. To investigate whether common variants ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, AT; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TV; Gerdes, AM; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DG; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TA; Meijers-Heijboer, HE; van der Hout, AH; Vreeswijk, MP; Hoogerbrugge, N; Ausems, MG; van Doorn, HC; Collée, JM; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, MK; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PD; Chenevix-Trench, G; Antoniou, AC; Friedman, E (2015-01)
      BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests ...
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

      George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
      Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. 

      Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; Vaz, F; Ray-Coquard, I; Stoppa-Lyonnet, D; Gonzalez-Martin, A; Sehouli, J; Colombo, N (2016-12)
      Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ...
    • Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. 

      George, A; Kaye, S; Banerjee, S (2017-05)
      The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA ...
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. 

      Copson, ER; Maishman, TC; Tapper, WJ; Cutress, RI; Greville-Heygate, S; Altman, DG; Eccles, B; Gerty, S; Durcan, LT; Jones, L; Evans, DG; Thompson, AM; Pharoah, P; Easton, DF; Dunning, AM; Hanby, A; Lakhani, S; Eeles, R; Gilbert, FJ; Hamed, H; Hodgson, S; Simmonds, P; Stanton, L; Eccles, DM (2018-02)
      BACKGROUND: Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect ...
    • Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. 

      Hallowell, N; Arden-Jones, A; Eeles, R; Foster, C; Lucassen, A; Moynihan, C; Watson, M (2006-11)
      Men and women who have a family history of breast and/or ovarian cancer may be offered a predictive genetic test to determine whether or not they carry the family specific BRCA1/2 mutation. The sons and daughters of mutation ...
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences. 

      Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; Zou, X; Martincorena, I; Alexandrov, LB; Martin, S; Wedge, DC; Van Loo, P; Ju, YS; Smid, M; Brinkman, AB; Morganella, S; Aure, MR; Lingjærde, OC; Langerød, A; Ringnér, M; Ahn, SM; Boyault, S; Brock, JE; Broeks, A; Butler, A; Desmedt, C; Dirix, L; Dronov, S; Fatima, A; Foekens, JA; Gerstung, M; Hooijer, GK; Jang, SJ; Jones, DR; Kim, HY; King, TA; Krishnamurthy, S; Lee, HJ; Lee, JY; Li, Y; McLaren, S; Menzies, A; Mustonen, V; O'Meara, S; Pauporté, I; Pivot, X; Purdie, CA; Raine, K; Ramakrishnan, K; Rodríguez-González, FG; Romieu, G; Sieuwerts, AM; Simpson, PT; Shepherd, R; Stebbings, L; Stefansson, OA; Teague, J; Tommasi, S; Treilleux, I; Van den Eynden, GG; Vermeulen, P; Vincent-Salomon, A; Yates, L; Caldas, C; van't Veer, L; Tutt, A; Knappskog, S; Tan, BK; Jonkers, J; Borg, Å; Ueno, NT; Sotiriou, C; Viari, A; Futreal, PA; Campbell, PJ; Span, PN; Van Laere, S; Lakhani, SR; Eyfjord, JE; Thompson, AM; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Martens, JW; Børresen-Dale, AL; Richardson, AL; Kong, G; Thomas, G; Stratton, MR (2016-06)
      We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ...
    • Management of breast cancer--part I. 

      Turner, NC; Jones, AL (2008-01)
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. 

      Pujade-Lauraine, E; Ledermann, JA; Selle, F; Gebski, V; Penson, RT; Oza, AM; Korach, J; Huzarski, T; Poveda, A; Pignata, S; Friedlander, M; Colombo, N; Harter, P; Fujiwara, K; Ray-Coquard, I; Banerjee, S; Liu, J; Lowe, ES; Bloomfield, R; Pautier, P; SOLO2/ENGOT-Ov21 investigators (2017-09)
      BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade ...
    • A paradox: urgent BRCA genetic testing. 

      Mitchell, G; Ardern-Jones, A; Kissin Mchir, M; Taylor, R; Eeles, RA (2001-01)
      Diagnostic or predictive testing for germline mutations in cancer predisposition genes is inherently slow as result of both genetic counselling and mutation analysis. The overall time taken for mutation testing is not ...
    • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. 

      Lecarpentier, J; Silvestri, V; Kuchenbaecker, KB; Barrowdale, D; Dennis, J; McGuffog, L; Soucy, P; Leslie, G; Rizzolo, P; Navazio, AS; Valentini, V; Zelli, V; Lee, A; Amin Al Olama, A; Tyrer, JP; Southey, M; John, EM; Conner, TA; Goldgar, DE; Buys, SS; Janavicius, R; Steele, L; Ding, YC; Neuhausen, SL; Hansen, TVO; Osorio, A; Weitzel, JN; Toss, A; Medici, V; Cortesi, L; Zanna, I; Palli, D; Radice, P; Manoukian, S; Peissel, B; Azzollini, J; Viel, A; Cini, G; Damante, G; Tommasi, S; Peterlongo, P; Fostira, F; Hamann, U; Evans, DG; Henderson, A; Brewer, C; Eccles, D; Cook, J; Ong, K-R; Walker, L; Side, LE; Porteous, ME; Davidson, R; Hodgson, S; Frost, D; Adlard, J; Izatt, L; Eeles, R; Ellis, S; Tischkowitz, M; EMBRACE; Godwin, AK; Meindl, A; Gehrig, A; Dworniczak, B; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Hahnen, E; Hauke, J; Rhiem, K; Kast, K; Arnold, N; Ditsch, N; Wang-Gohrke, S; Wappenschmidt, B; Wand, D; Lasset, C; Stoppa-Lyonnet, D; Belotti, M; Damiola, F; Barjhoux, L; Mazoyer, S; GEMO Study Collaborators; Van Heetvelde, M; Poppe, B; De Leeneer, K; Claes, KBM; de la Hoya, M; Garcia-Barberan, V; Caldes, T; Perez Segura, P; Kiiski, JI; Aittomäki, K; Khan, S; Nevanlinna, H; van Asperen, CJ; HEBON; Vaszko, T; Kasler, M; Olah, E; Balmaña, J; Gutiérrez-Enríquez, S; Diez, O; Teulé, A; Izquierdo, A; Darder, E; Brunet, J; Del Valle, J; Feliubadalo, L; Pujana, MA; Lazaro, C; Arason, A; Agnarsson, BA; Johannsson, OT; Barkardottir, RB; Alducci, E; Tognazzo, S; Montagna, M; Teixeira, MR; Pinto, P; Spurdle, AB; Holland, H; KConFab Investigators; Lee, JW; Lee, MH; Lee, J; Kim, S-W; Kang, E; Kim, Z; Sharma, P; Rebbeck, TR; Vijai, J; Robson, M; Lincoln, A; Musinsky, J; Gaddam, P; Tan, YY; Berger, A; Singer, CF; Loud, JT; Greene, MH; Mulligan, AM; Glendon, G; Andrulis, IL; Toland, AE; Senter, L; Bojesen, A; Nielsen, HR; Skytte, A-B; Sunde, L; Jensen, UB; Pedersen, IS; Krogh, L; Kruse, TA; Caligo, MA; Yoon, S-Y; Teo, S-H; von Wachenfeldt, A; Huo, D; Nielsen, SM; Olopade, OI; Nathanson, KL; Domchek, SM; Lorenchick, C; Jankowitz, RC; Campbell, I; James, P; Mitchell, G; Orr, N; Park, SK; Thomassen, M; Offit, K; Couch, FJ; Simard, J; Easton, DF; Chenevix-Trench, G; Schmutzler, RK; Antoniou, AC; Ottini, L (2017-07-10)
      Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge- ...
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. 

      Spurdle, AB; Couch, FJ; Parsons, MT; McGuffog, L; Barrowdale, D; Bolla, MK; Wang, Q; Healey, S; Schmutzler, R; Wappenschmidt, B; Rhiem, K; Hahnen, E; Engel, C; Meindl, A; Ditsch, N; Arnold, N; Plendl, H; Niederacher, D; Sutter, C; Wang-Gohrke, S; Steinemann, D; Preisler-Adams, S; Kast, K; Varon-Mateeva, R; Ellis, S; Frost, D; Platte, R; Perkins, J; Evans, DG; Izatt, L; Eeles, R; Adlard, J; Davidson, R; Cole, T; Scuvera, G; Manoukian, S; Bonanni, B; Mariette, F; Fortuzzi, S; Viel, A; Pasini, B; Papi, L; Varesco, L; Balleine, R; Nathanson, KL; Domchek, SM; Offitt, K; Jakubowska, A; Lindor, N; Thomassen, M; Jensen, UB; Rantala, J; Borg, Å; Andrulis, IL; Miron, A; Hansen, TV; Caldes, T; Neuhausen, SL; Toland, AE; Nevanlinna, H; Montagna, M; Garber, J; Godwin, AK; Osorio, A; Factor, RE; Terry, MB; Rebbeck, TR; Karlan, BY; Southey, M; Rashid, MU; Tung, N; Pharoah, PD; Blows, FM; Dunning, AM; Provenzano, E; Hall, P; Czene, K; Schmidt, MK; Broeks, A; Cornelissen, S; Verhoef, S; Fasching, PA; Beckmann, MW; Ekici, AB; Slamon, DJ; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Chang-Claude, J; Flesch-Janys, D; Rudolph, A; Seibold, P; Aittomäki, K; Muranen, TA; Heikkilä, P; Blomqvist, C; Figueroa, J; Chanock, SJ; Brinton, L; Lissowska, J; Olson, JE; Pankratz, VS; John, EM; Whittemore, AS; West, DW; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Devilee, P; Tollenaar, RA; Seynaeve, C; Van Asperen, CJ; Eccles, DM; Tapper, WJ; Durcan, L; Jones, L; Peto, J; dos-Santos-Silva, I; Fletcher, O; Johnson, N; Dwek, M; Swann, R; Bane, AL; Glendon, G; Mulligan, AM; Giles, GG; Milne, RL; Baglietto, L; McLean, C; Carpenter, J; Clarke, C; Scott, R; Brauch, H; Brüning, T; Ko, YD; Cox, A; Cross, SS; Reed, MW; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Gronwald, J; Dörk, T; Bogdanova, N; Park-Simon, TW; Hillemanns, P; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Burwinkel, B; Marme, F; Surovy, H; Yang, R; Anton-Culver, H; Ziogas, A; Hooning, MJ; Collée, JM; Martens, JW; Tilanus-Linthorst, MM; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Lindblom, A; Margolin, S; Joseph, V; Robson, M; Rau-Murthy, R; González-Neira, A; Arias, JI; Zamora, P; Benítez, J; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Peterlongo, P; Zaffaroni, D; Barile, M; Capra, F; Radice, P; Teo, SH; Easton, DF; Antoniou, AC; Chenevix-Trench, G; Goldgar, DE (2014-01)
      The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features thus have utility ...
    • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. 

      Kuchenbaecker, KB; Hopper, JL; Barnes, DR; Phillips, K-A; Mooij, TM; Roos-Blom, M-J; Jervis, S; van Leeuwen, FE; Milne, RL; Andrieu, N; Goldgar, DE; Terry, MB; Rookus, MA; Easton, DF; Antoniou, AC; BRCA1 and BRCA2 Cohort Consortium; McGuffog, L; Evans, DG; Barrowdale, D; Frost, D; Adlard, J; Ong, K-R; Izatt, L; Tischkowitz, M; Eeles, R; Davidson, R; Hodgson, S; Ellis, S; Nogues, C; Lasset, C; Stoppa-Lyonnet, D; Fricker, J-P; Faivre, L; Berthet, P; Hooning, MJ; van der Kolk, LE; Kets, CM; Adank, MA; John, EM; Chung, WK; Andrulis, IL; Southey, M; Daly, MB; Buys, SS; Osorio, A; Engel, C; Kast, K; Schmutzler, RK; Caldes, T; Jakubowska, A; Simard, J; Friedlander, ML; McLachlan, S-A; Machackova, E; Foretova, L; Tan, YY; Singer, CF; Olah, E; Gerdes, A-M; Arver, B; Olsson, H (2017-06-20)
      Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. Objectives: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer ...
    • The shieldin complex mediates 53BP1-dependent DNA repair. 

      Noordermeer, SM; Adam, S; Setiaputra, D; Barazas, M; Pettitt, SJ; Ling, AK; Olivieri, M; Álvarez-Quilón, A; Moatti, N; Zimmermann, M; Annunziato, S; Krastev, DB; Song, F; Brandsma, I; Frankum, J; Brough, R; Sherker, A; Landry, S; Szilard, RK; Munro, MM; McEwan, A; Goullet de Rugy, T; Lin, Z-Y; Hart, T; Moffat, J; Gingras, A-C; Martin, A; van Attikum, H; Jonkers, J; Lord, CJ; Rottenberg, S; Durocher, D (2018-08)
      53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini1,2. This function of 53BP1 requires interactions with PTIP3 and RIF14-9, ...
    • The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). 

      Leach, MO; Eeles, RA; Turnbull, LW; Dixon, AK; Brown, J; Hoff, RJ; Coulthard, A; Dixon, JM; Easton, DF; Evans, DG; Gilbert, FJ; Hawnaur, J; Hayes, C; Kessar, P; Lakhani, S; Liney, G; Moss, SM; Padhani, AP; Pointon, LJ; Sydenham, M; Walker, LG; Warren, RM; Haites, NE; Morrison, P; Cole, T; Rayter, Z; Donaldson, A; Shere, M; Rankin, J; Goudie, D; Steel, CM; Davidson, R; Chu, C; Ellis, I; Mackay, J; Hodgson, SV; Homfray, T; Douglas, F; Quarrell, OW; Eccles, DM; Gilbert, FG; Crothers, G; Walker, CP; Jones, A; Slack, N; Britton, P; Sheppard, DG; Walsh, J; Whitehouse, G; Teh, W; Rankin, S; Boggis, C; Potterton, J; McLean, L; Gordon, PA; Rubin, C (2002-09)
      The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS) is in progress. The study design, accrual to date, and related research projects are described. Revised accrual rates ...